Week in Medicine News and Research RSS Feed - Week in Medicine News and Research

Vaccine boosts advanced NSCLC patient survival

Vaccine boosts advanced NSCLC patient survival

Investigation of a vaccine targeting a glycoside present in non-small-cell lung cancer has demonstrated efficacy as a switch therapy for patients with stable, advanced disease after chemotherapy. [More]
Mutant allele frequency predicts lung cancer TKI response

Mutant allele frequency predicts lung cancer TKI response

Tyrosine kinase inhibitor sensitivity may be predicted by the frequency of a point mutation in the epidermal growth factor receptor gene, suggests a study of Japanese patients with advanced lung adenocarcinoma. [More]
Stereotactic radiosurgery feasible for multiple brain metastases

Stereotactic radiosurgery feasible for multiple brain metastases

Stereotactic radiosurgery is a feasible treatment option for cancer patients with up to 10 brain metastases, Japanese researchers report in The Lancet Oncology. [More]
High PD-L1 expression linked to reduced survival in NSCLC

High PD-L1 expression linked to reduced survival in NSCLC

Overexpression of programmed death-ligand 1 is independently associated with the presence of epidermal growth factor receptor gene mutations and poor prognosis in patients with non-small-cell lung cancer, Japanese researchers report. [More]
Preoperative ultrasound reveals NSCLC chest wall invasion

Preoperative ultrasound reveals NSCLC chest wall invasion

Surgeon-performed ultrasound is a good alternative to computed tomography for the identification of chest wall invasion in patients with non-small-cell lung cancer, suggests research demonstrating 90% sensitivity for detection of the spread. [More]
Pre-op PET/CT predicts stage I NSCLC adjuvant chemotherapy benefit

Pre-op PET/CT predicts stage I NSCLC adjuvant chemotherapy benefit

Preoperative imaging could help guide the use of postoperative adjuvant chemotherapy in patients with early non-small-cell lung cancer, Japanese researchers believe. [More]
Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Erlotinib feasible in KRAS wild-type lung adenocarcinoma

Erlotinib is a valid treatment option for patients with KRAS wild-type lung adenocarcinoma refractory to chemotherapy, study data show. [More]
EGFR biomarkers predict NSCLC response to vandetanib

EGFR biomarkers predict NSCLC response to vandetanib

Biomarker analyses of tumour samples from the ZODIAC study indicate that epidermal growth factor receptor gene copy number and mutation status may help identify the non-small-cell lung cancer patients most likely to benefit from treatment with vandetanib plus docetaxel. [More]
CD157 important in malignant pleural mesothelioma

CD157 important in malignant pleural mesothelioma

CD157 plays a pivotal role in the progression of malignant pleural mesothelioma and may be useful in the stratification of patients into different prognostic groups, Italian research suggests. [More]
Prognostic value of visceral plural invasion limited in part-solid lung cancer

Prognostic value of visceral plural invasion limited in part-solid lung cancer

Visceral plural invasion is a significant predictor of survival in patients with small solid lung tumours but not in patients with part-solid tumours, Japanese study findings indicate. [More]
Combined risk score enhances radiation pneumonitis prediction

Combined risk score enhances radiation pneumonitis prediction

Combining dose-volume histogram parameters with age and baseline pulmonary fibrosis score creates a novel predictive risk score that improves prediction of radiation pneumonitis in patients receiving concurrent chemoradiotherapy for non-small-cell lung cancer, research shows. [More]
Standard TFI definition still applies for relapsed SCLC classification

Standard TFI definition still applies for relapsed SCLC classification

Italian researchers have confirmed that using a treatment-free interval cut-off of 60 days to classify relapsed small-cell lung cancer as sensitive or resistant can be regarded as the standard definition. [More]
Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Researchers have identified additional resistance mechanisms that could be targeted to improve the efficacy of irreversible epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small-cell lung cancer harbouring both EGFR and T790M mutations. [More]

CRIPTO1 role in TKI resistance elucidated

Overexpression of CRIPTO1 may explain intrinsic tyrosine kinase inhibitor resistance in around 10% of patients with non-small-cell lung cancer and endothelial growth factor receptor mutations, research indicates. [More]
Collaboration classification useful for Japanese lung cancer patients

Collaboration classification useful for Japanese lung cancer patients

Epidermal growth factor receptor status and prognosis in Japanese patients can be predicted by a recently developed lung adenocarcinoma classification system, say researchers. [More]
TAZ represents a novel therapeutic target in NSCLC

TAZ represents a novel therapeutic target in NSCLC

Patients with non-small-cell lung cancer who express high levels of transcriptional coactivator with PDZ-binding motif may be a clinically distinct subgroup with an unfavourable prognosis, researchers report. [More]
CIP2A pathway involved in erlotinib response

CIP2A pathway involved in erlotinib response

Researchers have identified a novel mechanism, involving the cancerous inhibitor of protein phosphatase 2A pathway, which mediates the anti-tumour effects of erlotinib in non-small-cell lung cancer cells without epidermal growth factor receptor mutations. [More]
Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Erlotinib can be intercalated with the anti-tubule agent eribulin mesylate for patients with advanced non-small-cell lung cancer but it is unlikely to increase treatment efficacy in those without epidermal growth factor receptor activating mutations, research suggests. [More]

Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Phase II study findings show only marginal positive effects of third-line treatment with afatinib for advanced non-small-cell lung cancer in patients with wild-type epidermal growth-factor receptor tumour status. [More]
Six-gene signature predicts survival after targeted therapy for NSCLC

Six-gene signature predicts survival after targeted therapy for NSCLC

The presence of a six-gene profile in the microRNA of patients with advanced non-squamous non-small-cell lung cancer predicts reduced survival likelihood after first-line treatment with targeted therapy followed by chemotherapy for disease progression, indicate research results. [More]